Click Therapeutics

Executive Summary

Click Therapeutics is a privately held digital therapeutics company headquartered in New York, founded in 2012, that combines neuroscience with software to develop prescription digital treatments and software-enhanced drug therapies. The company focuses on central nervous system (CNS) disorders and operates at the intersection of digital health and neuroscience. Its lead assets are in Phase 3 development, targeting conditions such as major depressive disorder, insomnia, and smoking cessation. Click's platform leverages proprietary algorithms and behavioral science to deliver personalized, scalable interventions that aim to improve patient outcomes while reducing healthcare costs. With a strong intellectual property portfolio and collaborations with pharmaceutical partners, Click is poised to disrupt traditional CNS treatment paradigms by offering software-based alternatives or synergies with pharmacotherapy. The company has not yet achieved FDA clearance for any product but expects pivotal data from ongoing trials in the near term. Given the increasing regulatory acceptance of digital therapeutics and the growing demand for non-pharmacological interventions, Click Therapeutics represents a high-potential player in the digital health space.

Upcoming Catalysts (preview)

• Q2 2026FDA approval decision for CT-133 (treatment of major depressive disorder)70% success
• Q1 2026Phase 3 top-line data readout for CT-155 (insomnia)75% success
• Q3 2026Potential Series D or strategic partnership announcement with a major pharmaceutical company80% success